晨光生物(300138.SZ):延長公開發行可轉債股東大會決議有效期和授權有效期
格隆匯3月31日丨晨光生物(300138.SZ)公佈,公司於2019年4月4日、2019年4月24日分別召開第三屆董事會第二十九次會議、2019年第一次臨時股東大會,審議通過了公司公開發行可轉換公司債券相關議案,並授權董事會全權辦理此次公開發行可轉換公司債券的相關事宜。
2019年12月16日公司收到中國證券監督管理委員會出具的《關於核准晨光生物科技集團股份有限公司公開發行可轉換公司債券的批覆》。
鑑於此次發行方案及授權決議有效期將到期,為保證此次公開發行可轉換公司債券工作的持續、有效,確保公開發行可轉換公司債券有關事宜順利推進,公司於2020年3月31日召開了第四屆董事會第十五次會議和第四屆監事會第九次會議,審議通過了《關於延長公開發行可轉換公司債券股東大會決議有效期的議案》和《關於提請股東大會延長授權公司董事會全權辦理此次公開發行可轉換公司債券相關事宜有效期的議案》,同意將此次公開發行可轉換公司債券股東大會決議有效期及授權有效期自前次有效期屆滿之日起延長6個月(即2020年10月23日)。
除上述延長股東大會決議有效期及授權有效期外,此次公開發行可轉換公司債券其他內容不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.